ISRCTN ISRCTN17866568
DOI https://doi.org/10.1186/ISRCTN17866568
Integrated Research Application System (IRAS) 1013458
Sponsor Lundbeck (Denmark)
Funder H. Lundbeck A/S
Submission date
09/07/2026
Registration date
09/07/2026
Last edited
09/07/2026
Recruitment status
No longer recruiting
Overall study status
Deferred
Condition category
Other
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.

Contact information

Dr Jonathan Ackroyd
Principal investigator, Public, Scientific

Drapers Yard, Marshall St, Holbeck
Leeds
LS11 9EH
United Kingdom

Phone +44 1133013645
Email Jonathan.Ackroyd@fortrea.com

Study information

Primary study designInterventional
AllocationN/A: single arm study
MaskingOpen (masking not used)
ControlUncontrolled
AssignmentSingle
PurposeMetabolism and bioavailability
Scientific titleDeferred registration: Fortrea code: 780587
Full scientific title to be added on or before the deferral expiry date
Study objectives The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.
Ethics approval(s)

Approved 04/03/2026, London - Brent Research Ethics Committee (Health Research Authority, 2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; no telephone number provided; brent.rec@hra.nhs.uk), ref: 26/LO/0019

Health condition(s) or problem(s) studiedThe Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.
InterventionThe Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.
Intervention typeDrug
PhasePhase I
Drug / device / biological / vaccine name(s)The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date
Primary outcome measure(s)
  1. [Outcome] measured using [measure] at [timepoint]. The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.
Key secondary outcome measure(s)
Completion date20/07/2027

Eligibility

Participant type(s)
Age groupAdult
Lower age limit35 Years
Upper age limit55 Years
SexAll
Target sample size at registration15
Key inclusion criteriaThe Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.
Key exclusion criteriaThe Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.
Date of first enrolment08/07/2026
Date of final enrolment14/08/2026

Locations

Countries of recruitment

  • United Kingdom
  • England

Study participating centre

Fortrea Clinical Research Unit
Drapers Yard, Marshall St, Holbeck
Leeds
LS11 9EH
England

Results and Publications

Individual participant data (IPD) Intention to shareNo

Editorial Notes

09/07/2026: Trial's existence confirmed by London - Brent Research Ethics Committee.